Skip to main content
1916 search results for:

Bullous Pemphigoid 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 05-03-2024 | Bullous Pemphigoid | Online First

    Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT

    Bullous pemphigoid (BP) is the most common autoimmune skin-blistering disease. BP is associated with autoantibodies directed against the hemidesmosome transmembrane BP180 and/or intracellular BP230 proteins, which are responsible for adhesion and …

  2. Open Access 29-12-2023 | Bullous Pemphigoid | ReviewPaper

    Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

    Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied …

  3. 01-03-2024 | Shingles | Letter

    Risk and determinants of herpes zoster in bullous pemphigoid: a large-scale population-based study

  4. 28-10-2023 | Bullous Pemphigoid | ReviewPaper

    Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches

    Bullous pemphigoid is one of the most common autoimmune bullous diseases occurring primarily in the elderly. Pathogenic autoantibodies against BP180 and BP230 at the dermal–epidermal junction cause subepidermal blisters, erosions, and intense …

  5. Open Access 06-12-2023 | Bullous Pemphigoid | Online First

    A case of bullous pemphigoid and renal disease after dipeptidyl peptidase 4 inhibitor administration

    A 62-year-old man with type 2 diabetes was admitted because of a decrease in estimated glomerular filtration rate from 72 to 17.5 mL/min/1.73 m2 in 10 years and development of widespread bullous skin lesions. His hemoglobin A1c level had been …

  6. 29-09-2023 | Bullous Pemphigoid | OriginalPaper

    Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid

    Nivolumab, a human immunoglobulin G4 monoclonal antibody targeting programmed cell death-1 (PD-1) receptors, has been approved to treat a variety of malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma. The most …

  7. 14-08-2022 | Etanercept | ReviewPaper

    Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review

    Psoriasis in an immune-mediated inflammatory disease and is associated with increased risk of various comorbidities, especially autoimmune bullous diseases. However, the optimal management of coexisting psoriasis and bullous pemphigoid (BP) is not …

  8. Open Access 01-12-2022 | Lung Cancer | OriginalPaper

    Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy:  a case report

    Several case reports have described the association of different types of malignancy with bullous pemphigoid, but a direct paraneoplastic correlation has not been proven. Bullous pemphigoid (BP) is a chronic, autoimmune, subepidermal, blistering …

  9. 14-07-2022 | Bullous Pemphigoid | OriginalPaper

    Association between bullous pemphigoid and atopic dermatitis: a population-based case–control study in Taiwan

    Although bullous pemphigoid (BP) and atopic dermatitis (AD) share pathogenic mechanisms, their relationship remains controversial. Therefore, we conducted a population-based case–control study to investigate the association between BP and AD in …

  10. 19-05-2023 | Bullous Pemphigoid | OriginalPaper

    Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are positively correlated with disease activity of bullous pemphigoid

    Bullous pemphigoid (BP) is a complex inflammatory process with elevated levels of autoantibodies, eosinophils, neutrophils, and various cytokines. Hematological inflammatory biomarkers can reflect inflammatory state in various diseases. Up to now …

  11. 17-05-2022 | Bullous Pemphigoid | OriginalPaper

    Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study

    Bullous pemphigoid (BP) is the most common autoimmune bullous disease, and its annual incidence has risen in the past decade [ 1 , 2 ]. The 1-year mortality rate in patients with BP after the confirmation of diagnosis is up to 16.7–26.7% [ 1 , 3 – …

  12. Open Access 01-12-2021 | Bullous Pemphigoid | ReviewPaper

    Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin

    Bullous pemphigoid (BP) is the most common autoimmune bullous skin disease that affects primarily patients older than 60 years. The majority of BP cases are spontaneous, but BP can also be triggered by certain drugs’ exposures. Since 2011, a …

  13. Open Access 15-01-2022 | Bullous Pemphigoid | OriginalPaper

    Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation

    The timing pattern in which dipeptidyl-peptidase IV inhibitors (DPP4i) confer the risk of bullous pemphigoid (BP) is unknown. To investigate the odds of BP following exposure to DPP4i and to perform a duration-response analysis evaluating the risk …

  14. 01-06-2021 | Bullous Pemphigoid | News

    Dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid

  15. Open Access 01-12-2021 | Bullous Pemphigoid | OriginalPaper

    The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

    Bullous pemphigoid (BP) is the most common chronic bullous autoimmune skin disease which is characterized by the presentation of subepidermical blisters. It is considered as a disease of the elderly people and is associated with significant …

  16. 03-03-2023 | Bullous Pemphigoid | ReviewPaper

    Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis

    Bullous pemphigoid (BP) is an uncommon autoimmune [ 1 ] bullous disorder with increasing prevalence worldwide [ 2 , 3 ]. Although it can affect people of all ages, BP is more commonly found in adults over the age of 60 [ 4 , 5 ] and is …

  17. Open Access 01-12-2021 | Knee-TEP | OriginalPaper

    Diagnosis and treatment of bullous pemphigoid that developed twice after total knee replacement arthroplasty: a case report

    Total knee replacement arthroplasty (TKA) is frequently performed in South Korea (approximately 70,000 cases in 2013 alone) [ 1 ]. Simple swelling-associated blistering around the periphery of the operative wound is a well-known adverse effect; the …

  18. Open Access 12-08-2022 | Bullous Pemphigoid | BriefCommunication

    Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance

    Autoimmune bullous disease autoantibodies, particularly including bullous pemphigoid (BP)-related anti-BP180-NC16A IgG, have been reported in a small subset of healthy individuals, but information about associated factors is lacking. We …

  19. 01-07-2021 | Sleep Apnea | OriginalPaper

    Association of bullous pemphigoid and comorbid health conditions: a case–control study

    Bullous pemphigoid (BP) is an autoimmune blistering disorder that is caused by autoantibodies against components of the hemidesmosome, followed by either complement activation and/or non-complemental blistering mechanisms [ 1 ]. BP predominantly …

  20. Open Access 10-02-2023 | Bullous Pemphigoid | OriginalPaper

    Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patients

    Bullous pemphigoid (BP) is an autoimmune blistering disease that targets the haemidesmosomal proteins, mainly BP180. Extracellular vesicles (EVs) have been demonstrated to carry tissue-specific autoantigens in the setting of autoimmune diseases …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.